Targeting RNA Polymerase II to improve treatment for Acute Myeloid Leukemia
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10880377
This study is looking at how to make current treatments for Acute Myeloid Leukemia work better, especially for patients whose cancer is tough to treat because of certain mutations, by focusing on a specific part of the cell's machinery that helps cancer grow.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10880377 on ClinicalTrials.gov |
What this research studies
This research investigates how RNA Polymerase II can be targeted to enhance the effectiveness of existing therapies for Acute Myeloid Leukemia (AML), particularly in cases where mutations in the RAS signaling pathway lead to treatment resistance. The approach involves identifying key components of the RNA Polymerase II pathway that contribute to this resistance and testing existing inhibitors in laboratory models and patient samples. By understanding the transcriptional changes associated with RAS activation and FLT3 inhibition, the research aims to find new therapeutic strategies for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia, especially those with FLT3 mutations and RAS pathway activation.
Not a fit: Patients with AML who do not have FLT3 mutations or RAS pathway activation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with AML, particularly those with RAS mutations who currently have limited options.
How similar studies have performed: Other research has shown promising results in targeting RNA Polymerase II and related pathways in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SMITH, CATHERINE CHOY — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SMITH, CATHERINE CHOY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.